Newborns in Gloucestershire to benefit from groundbreaking Genomic Study

This pioneering research initiative, led by Genomics England and supported by NHS England, aims to transform the diagnosis and treatment of rare genetic conditions in babies by offering whole genome sequencing shortly after birth. The study will recruit up to 100,000 babies across England to explore how genomic sequencing can identify over 200 rare, early-onset, and treatable conditions.

Participating sites within the Trust include Gloucester Royal Hospital and Stroud Maternity Hospital.

Noel Peter, Director for Research, Innovation and Genomics at Gloucestershire Hospitals, said: "This is a significant step forward in our commitment to research and innovation. By taking part in the Generation Study, we’re helping shape the future of personalised medicine and giving families access to potentially life-changing insights."

The aim of the Generation Study is to determine whether offering whole genome sequencing to newborns can help identify rare genetic conditions early — often before symptoms appear — and enable faster access to treatment and support. The study also seeks to understand how this approach could be integrated into routine NHS care in the future.

Eligible parents will be invited to participate during pregnancy, with information provided through midwives, posters, and digital channels. Participation is voluntary, and all data will be handled with the highest standards of privacy and ethics.

For more information, you can contact the team at ghn-tr.generation.glos@nhs.net or visit www.generationstudy.co.uk.